Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

32.88 -0.18 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180,187
Open 33.15
Bid (Size) 27.50 (1)
Ask (Size) 40.00 (6)
Prev. Close 33.06
Today's Range 32.71 - 33.80
52wk Range 23.15 - 39.33
Shares Outstanding 43,862,850
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunocore (IMCR) Q2 Revenue Jumps 30%
Via The Motley Fool
Topics Earnings Intellectual Property
Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growth
Immunocore (IMCR) beat Q2 2025 estimates with $98M revenue (+30% YoY) and a narrower EPS loss. KIMMTRAK sales surged 32%, while pipeline progress and strong cash position ($882.8M) boosted investor... 
Via Chartmill

Performance

YTD
+10.3%
+10.3%
1 Month
-9.2%
-9.2%
3 Month
+6.1%
+6.1%
6 Month
+12.6%
+12.6%
1 Year
-9.7%
-9.7%

More News

Read More
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
Via Benzinga
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
From Immunocore Holdings plc
Via GlobeNewswire
Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
Via Benzinga
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Analyst Expectations For Immunocore Holdings's Future
Via Benzinga
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
What Analysts Are Saying About Immunocore Hldgs Stock
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Analyst Expectations For Immunocore Hldgs's Future
Via Benzinga
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
From Immunocore Holdings plc
Via GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Via Benzinga
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire

Frequently Asked Questions

Is Immunocore Holdings plc - American Depositary Shares publicly traded?
Yes, Immunocore Holdings plc - American Depositary Shares is publicly traded.
What exchange does Immunocore Holdings plc - American Depositary Shares trade on?
Immunocore Holdings plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Immunocore Holdings plc - American Depositary Shares?
The ticker symbol for Immunocore Holdings plc - American Depositary Shares is IMCR on the Nasdaq Stock Market
What is the current price of Immunocore Holdings plc - American Depositary Shares?
The current price of Immunocore Holdings plc - American Depositary Shares is 32.88
When was Immunocore Holdings plc - American Depositary Shares last traded?
The last trade of Immunocore Holdings plc - American Depositary Shares was at 08/15/25 04:00 PM ET
What is the market capitalization of Immunocore Holdings plc - American Depositary Shares?
The market capitalization of Immunocore Holdings plc - American Depositary Shares is 1.44B
How many shares of Immunocore Holdings plc - American Depositary Shares are outstanding?
Immunocore Holdings plc - American Depositary Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.